Search results for "State."

showing 10 items of 8943 documents

Prognosis and cure of long-term cancer survivors: A population-based estimation.

2019

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.…

0301 basic medicineOncologyMaleCancer ResearchTime FactorsSettore MED/42 - Igiene Generale E Applicata0302 clinical medicineCancer SurvivorsProstateNeoplasmsThyroid cancerOriginal Researcheducation.field_of_studyRelative survivalMortality rateMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosispopulation-based cancer registriemedicine.anatomical_structureOncologyItaly030220 oncology & carcinogenesiscancer cure Italy population-based cancer registries prevalence survivalFemaleCancer PreventionAdultmedicine.medical_specialtypopulation-based cancer registriesAdolescentPopulationprevalenceSocio-culturalelcsh:RC254-282survival03 medical and health sciencesYoung AdultLife ExpectancyInternal medicinemedicinepopulation‐based cancer registriesHumansRadiology Nuclear Medicine and imagingcancer cureeducationAgedEstimationbusiness.industryCancerModels Theoreticalmedicine.disease030104 developmental biologyLife expectancycancer cure; Italy; population-based cancer registries; prevalence; survivalbusinessCancer medicine
researchProduct

Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review

2016

Prostate cancer, the second most frequently diagnosed cancer in males worldwide, is estimated to be diagnosed in 1.1 million men per year. Introduction of PSA testing substantially improved early detection of prostate cancer, however it also led to overdiagnosis and subsequent overtreatment of patients with an indolent disease. Treatment outcome and management of prostate cancer could be improved by the development of non-invasive biomarker assays that aid in increasing the sensitivity and specificity of prostate cancer screening, help to distinguish aggressive from indolent disease and guide therapeutic decisions. Prostate cancer cells release miRNAs into the bloodstream, where they exist …

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyOverdiagnosisDiseaseReviewExosomesManagement of prostate cancer03 medical and health sciencesProstate cancer0302 clinical medicinePredictive Value of TestsInternal medicinemedicineBiomarkers TumorHumansCell-free miRNAsGenetic TestingLiquid biopsyOverdiagnosisProstate cancerLiquid biopsybusiness.industryGene Expression ProfilingCancerDisease ManagementProstatic NeoplasmsBiological TransportExtracellular vesiclesmedicine.diseasePrognosisBody FluidsMicroRNAs030104 developmental biologyProstate cancer screeningOncology030220 oncology & carcinogenesisImmunologyMolecular MedicineBiomarker (medicine)businessTranscriptomeMicrovesiclesBiomarkersMolecular Cancer
researchProduct

Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.

2017

The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA res…

0301 basic medicineOncologyMalemedicine.medical_specialtyCancer ResearchDocetaxelprostatic neoplasm03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineabirateroneAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPharmacology (medical)Neoplasm MetastasisSurvival rateAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryandrogen antagonistRetrospective cohort studyMiddle AgedProstate-Specific Antigenmedicine.diseasedrug therapyProstate-specific antigenProstatic Neoplasms Castration-Resistant030104 developmental biologyDocetaxelTolerabilitymetastatic castration-resistant prostate cancerOncology030220 oncology & carcinogenesisPrednisoneAndrostenesKallikreinsTaxoidsbusinessmedicine.drugAnti-cancer drugs
researchProduct

Quantitative determination of tumor platinum concentration of patients with advanced Breast, lung, prostate, or colorectal cancers undergone platinum…

2017

Context: Previous studies have reported direct relationship between tumor reduction and its platinum concentration following platinum-based (Pt-based) chemotherapy. However, quantitative data of tumor platinum concentration have not yet been reported for the most common cancers. Aims: Determination of tumor platinum concentration of breast, lung, prostate, and colorectal cancers after Pt-based chemotherapy; and evaluation of the influence of chemo drug type, chemotherapy regimen, and time lapse from last chemotherapy on tumor platinum concentration. Materials and Methods: Tumor samples of patients with advanced breast, lung, prostate, and colorectal cancers undergone Pt-based chemotherapy w…

0301 basic medicineOncologyMalemedicine.medical_specialtyLung NeoplasmsColorectal cancermedicine.medical_treatmentcolorectal cancerBreast Neoplasmsplatinum concentrationlcsh:RC254-28203 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerBreast cancerDrug TherapyProstateInternal medicineNeoplasmsmedicineHumansRadiology Nuclear Medicine and imagingLung cancerPlatinumChemotherapybusiness.industryProstatic NeoplasmsGeneral Medicinemedicine.diseaseprostate cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenRegimenlung cancer030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemalebusinessColorectal NeoplasmsJournal of cancer research and therapeutics
researchProduct

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

2019

AbstractBackgroundNeoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology.DesignA panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer.ResultsNeoadjuvant therapy has equivalent efficacy to adjuvant therapy, and it has some additional benefits that include increasing breast conser…

0301 basic medicineOncologyPosition statementCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineBreast CancermedicineAdjuvant therapyHumansRadical surgeryskin and connective tissue diseasesNeoadjuvant therapyEarly breast cancerChemotherapybusiness.industrymedicine.diseaseNeoadjuvant Therapy030104 developmental biologyOncology030220 oncology & carcinogenesisHormonal therapyFemalebusinessThe Oncologist
researchProduct

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized t…

2019

Highlights • Hormonal receptors positive breast tumor and prostate cancer are managed with endocrine therapies. • Endocrine therapies designed for breast and prostate cancer are often associated to serious adverse skeletal related events, such fractures. • Denosumab is a monoclonal anti-body binding RANKL which acts as inhibitor of osteoclasts activity, thus increasing bone mass. • Denosumab was showed to strongly prevent hormonal therapies-related skeletal issues. • Denosumab administration results safe in bone mass increase and reduction of fractures risk.

0301 basic medicineOncologyRCTs randomized clinical trialrandomized clinical trialslcsh:Diseases of the musculoskeletal systemSettore MED/06 - Oncologia MedicaOsteoporosisBMD bone mass densityReview Articleandrogen deprivation therapyADTlaw.inventionAndrogen deprivation therapyProstate cancerhazard ratio0302 clinical medicineRandomized controlled triallawHRMedicineBreastSAEsCancerProstateRANKLCIMD mean differencelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRCTs randomized clinical trialsDenosumabOncology030220 oncology & carcinogenesisSAEs serious adverse eventsDenosumabmean differencemedicine.drugmedicine.medical_specialtylcsh:RC254-28203 medical and health sciencesBreast cancerRANKL receptor activator of nuclear factor-kB ligandBMDInternal medicineAdverse effectADT androgen deprivation therapyRCTsbusiness.industryMDmedicine.diseaseHR hazard ratioHormonereceptor activator of nuclear factor-kB ligandDiscontinuationCI confidence interval030104 developmental biologyFractureconfidence intervalADT androgen deprivation therapy; BMD bone mass density; Breast; CI confidence interval; Cancer; Denosumab; Fracture; HR hazard ratio; Hormone; MD mean difference; Prostate; RANKL receptor activator of nuclear factor-kB ligand; RCTs randomized clinical trials; SAEs serious adverse eventsserious adverse eventsbone mass densitylcsh:RC925-935businessJournal of Bone Oncology
researchProduct

Short telomere length is associated with impaired cognitive performance in European ancestry cohorts

2017

AbstractThe association between telomere length (TL) dynamics on cognitive performance over the life-course is not well understood. This study meta-analyses observational and causal associations between TL and six cognitive traits, with stratifications on APOE genotype, in a Mendelian Randomization (MR) framework. Twelve European cohorts (N=17 052; mean age=59.2±8.8 years) provided results for associations between qPCR-measured TL (T/S-ratio scale) and general cognitive function, mini-mental state exam (MMSE), processing speed by digit symbol substitution test (DSST), visuospatial functioning, memory and executive functioning (STROOP). In addition, a genetic risk score (GRS) for TL includin…

0301 basic medicineOncologycognitionNetherlands Twin Register (NTR)Psychometricsgenetic associationgenotypepolymerase chain reactionStatistics as TopicNeuropsychological Testsgenetic riskDISEASE3124 Neurology and psychiatryCohort Studies0302 clinical medicinesingle nucleotide polymorphismcognitive defectYOUNG-ADULTSgenetic variabilitytelomere lengthMedicineGWAScognitive performanceta515depth perceptionNetherlandsRISKlearningmedicine.diagnostic_testdigit symbol substitution testquantitative analysisDEMENTIAGenetic Carrier ScreeningadultarticleMini Mental State ExaminationCognitionta3142episodic memoryznf208 geneMiddle AgedTelomereapolipoprotein E4cohort analysisrtel1 genePsychiatry and Mental healthPROCESSING SPEEDacyp2 genefemaleancestry groupMENDELIAN RANDOMIZATIONOriginal ArticleClinical psychologymedicine.medical_specialtytert genePsychometricsMendelian randomization analysisgenetic risk scoreWhite People03 medical and health sciencesCellular and Molecular NeurosciencemaleInternal medicineMendelian randomizationpleiotropyJournal Article/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_HumansCognitive DysfunctionEffects of sleep deprivation on cognitive performancehumangeneBiological PsychiatryMETAANALYSISAgedterc geneStroop testMini–Mental State Examinationgenome-wide association studyIDENTIFICATIONPsykologi (exklusive tillämpad psykologi)business.industryMORTALITYobfc1 genemajor clinical studyConfidence intervalPsychology (excluding Applied Psychology)030104 developmental biologyexecutive functionDigit symbol substitution testnaf1 geneobservational studybusiness030217 neurology & neurosurgeryStroop effect
researchProduct

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer

2018

Giuseppe Cicero,1 Rossella De Luca,1 Francesco Dieli2 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, Palermo, Italy Background: In many clinical trials designed to assess the efficacy of anticancer treatments, overall survival (OS) is often used as a primary endpoint despite its several points of weakness. Methods: This study evaluated the role of progression-free survival (PFS) in the first three lines of treatment as a potential surrogate endpoint of OS in patients with metastatic colorectal cancer (MCRC). One hu…

0301 basic medicineOncologymedicine.medical_specialtycolorectal neoplasm overall survival progression-free survival surrogate endpoint liver metastates avastin egorafenibColorectal canceroverall survivalegorafenibOncoTargets and Therapy03 medical and health sciences0302 clinical medicineInternal medicinesurrogate endpoint liver metastatesOverall survivalClinical endpointMedicinePharmacology (medical)In patientProgression-free survivalavastinOriginal Researchbusiness.industryTime to progressionSurrogate endpointmedicine.diseaseClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesiscolorectal neoplasmbusinessprogression-free survivalOncoTargets and Therapy
researchProduct

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer

2017

Abstract: Prostate cancer is the second most diagnosed cancer in males in the world. Plasma quantification of prostate-specific antigen substantially improved the early detection of prostate cancer, but still lacks the required specificity. Clinical management of prostate cancer needs advances in the development of new non-invasive biomarkers, ameliorating current diagnosis and prognosis and guiding therapeutic decisions. microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level. These miRNAs are expressed in the cells and are also present in cell-derived extracellular vesicles such as exosomes. Exosomes have been shown to act as…

0301 basic medicinePCA3MaleCancer ResearchBiomarker; Exosome; Liquid biopsies; MiRNAs; Prostate cancerBioinformaticsExosomesExosome03 medical and health sciencesProstate cancer0302 clinical medicineProstateLiquid biopsiemicroRNABiomarkers TumorMedicineHumansLiquid biopsyProstate cancerbusiness.industryLiquid BiopsyCancerProstatic NeoplasmsGeneral MedicineBiomarkermedicine.diseaseMicrovesiclesExosomeMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchHuman medicinebusinessMiRNA
researchProduct

Reductive Stress: A New Concept in Alzheimer's Disease

2015

Reactive oxygen species play a physiological role in cell signaling and also a pathological role in diseases, when antioxidant defenses are overwhelmed causing oxidative stress. However, in this review we will focus on reductive stress that may be defined as a pathophysiological situation in which the cell becomes more reduced than in the normal, resting state. This may occur in hypoxia and also in several diseases in which a small but persistent generation of oxidants results in a hormetic overexpression of antioxidant enzymes that leads to a reduction in cell compartments. This is the case of Alzheimer's disease. Individuals at high risk of Alzheimer's (because they carry the ApoE4 allele…

0301 basic medicinePathologymedicine.medical_specialtyAntioxidantmedicine.medical_treatmentDiseaseBiologymedicine.disease_cause03 medical and health sciencesAlzheimer DiseasemedicineAnimalsHumanschemistry.chemical_classificationReactive oxygen speciesResting state fMRIHormesisHypoxia (medical)medicine.disease030104 developmental biologyNeurologychemistryImmunologyNeurology (clinical)medicine.symptomAlzheimer's diseaseOxidation-ReductionOxidative stress
researchProduct